This case report describes the first use of the investigational antiviral drug pocapavir for severe neonatal enteroviral sepsis.
May inform future trials of pocapavir in neonatal enteroviral sepsis; leaves open its role pending controlled data.
Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3.
No takes yet. Share an insight, caveat, or question.
Torres‐Torres et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: